Drugmakers hiked prices 1,000% in massive price-fixing scheme, states allege | Ars Technica


Twenty leading drug companies—including Teva Pharmaceuticals, Pfizer, Novartis, and Mylan—were in cahoots for years to fix and dramatically inflate the prices of more than 100 generic drugs, in some cases to raising prices “well over 1,000 percent,” according to a lawsuit filed late last week by 44 states.The alleged scheme was intended to ensure that each company was a “responsible competitor” who was “playing nice in the sandbox” to get its “fair share” of profits from the drugs. Those drugs included pills, capsules, ointments, and cream. They range from oral antibiotics, blood thinners, cancer drugs, contraceptives, statins, anti-inflammatory drugs, anti-depressants, blood pressure medications, drugs used to treat HIV, and drugs for ADHD. A full list of the generic drugs can be found here.”We all know that prescription drugs can be expensive,” said New Jersey Attorney General Gurbir S. Grewal in a statement. “Now we know that high drug prices have been driven in part by an illegal conspiracy among generic drug companies to inflate their prices.”

Source: Drugmakers hiked prices 1,000% in massive price-fixing scheme, states allege | Ars Technica

Mylan chairman: Drug pricing critics ought to go copulate with themselves | Ars Technica UK


Mr. Coury replied that he was untroubled. He raised both his middle fingers and explained, using colorful language, that anyone criticizing Mylan, including its employees, ought to go copulate with themselves. Critics in Congress and on Wall Street, he said, should do the same. And regulators at the Food and Drug Administration? They, too, deserved a round of anatomically challenging self-fulfillment.

Source: Mylan chairman: Drug pricing critics ought to go copulate with themselves | Ars Technica UK

For ripping off Medicaid, EpiPen maker Mylan pays Feds $465 million | Ars Technica


In settlement, Mylan doesn’t admit guilt for misclassifying life-saving device.

Source: For ripping off Medicaid, EpiPen maker Mylan pays Feds $465 million | Ars Technica

EpiPen Uproar Highlights Company’s Family Ties to Congress


The CEO of a former Fortune 500 company, who is also the daughter of a U.S. senator, is under fire for jacking up the rates of a life-saving anti-allergy treatment.

Source: EpiPen Uproar Highlights Company’s Family Ties to Congress